A Study on Clinical Profile and Antimicrobial Drug Resistance in Infection with Stenotrophomonas maltophilia at a Tertiary Care Hospital of Rural Gujarat, India.
A Study On Clinical Profile And Antimicrobial Drug Resistance In Infection With Stenotrophomonas Maltophilia
DOI:
https://doi.org/10.70284/njirm.v7i5.1128Keywords:
Stenotrophomonas maltophilia, Prevalence, Antimicrobial drug resistanceAbstract
Background & objectives: Stenotrophomonas maltophilia causes opportunistic infections and is emerging as an important hospital-acquired pathogen. Present study was undertaken to investigate the prevalence, clinical profile, associated factors and antimicrobial susceptibility of S. maltophilia. Methods: Cross sectional retrospective study was conducted whereby patients’ details including type of infection, hospital stay, indwelling devices, co-morbid conditions and outcome till discharge were collected from January 2012 to March 2016. Identification and antimicrobial susceptibility were done by using Vitek2-compact-microbiological system. Results: 45 (0.17%) S.maltophilia strains were isolated from 27,132 samples received, forming 1.63% of total non-fermenters. Prevalence of S.maltophilia infection ranged from 0.06% in 2012 to 0.26% in 2015. Common sites involved were respiratory tract i.e. 55.5%, followed by bloodstream (20%), urinary tract (13.3%) and soft tissue (11.1%). 64.4% patients were male, and adults (26.7%) between 51-60 years of age. 66.7% of the isolates were from critical care units followed by wards (33.3%). Co-morbid conditions observed were COPD with respiratory complications i.e. 26.7% followed by cardiovascular diseases 22.2%, malignancy 11.1%, post surgical patients 11.1%, complicated UTI and trauma 8.8% each, CNS complications 6.7%, burns and cellulitis 2.2% each. All patients had exposure to broad-spectrum antibiotics and 66.6% had indwelling devices. 17.8% isolates were resistant to trimethoprim-sulfamethoxazole. Mortality observed was 20%. Interpretation & conclusion: S maltophilia is an emerging pathogen and its prevalence has gradually increased at our hospital. ICUs are the main hospital sites and respiratory infections main clinical condition. [Disha S NJIRM 2016; 7(5):5-8]
References
2. Yinghong Ji, Chunhul Jiang, Jian Ji, Yi Luo, Yongxiang Jiang and Yi Lu. Post-cataract enophthalmitis caused by multidrug-resistant S. maltophilia: clinical features and risk factors. BioMed central Ophthalmology. 2015; 15(14):1-8.
3. Chang Y-T, Lin C-Y and Hsueh P-R. Update on infections caused by S. maltophilia with particularattention to resistance mechanisms and therapeutic options. Front Microbiol. 2015; 893(6):1-20.
4. Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ. S. maltophilia emerging disease patterns and challenges for treatment. Expert Rev. Anti Infect.Ther. 2011; 9(4):471-488.
5. Brooke JS New strategies against S. maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert. Rev.Anti Infect. Ther. 2014; 12(1):1-4.
6. Sung-Yeon Cho, Dong-Gun Lee, Su-Mi Choi, Chulmin Park, Hye-Su n Chun, Yeon-Joon Park, Jae-Ki Choi, et.al., S. maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations. BioMed Central Infectious Disease. 2015; 15:69:1-8.
7. Brooke JS: S. maltophilia: an emerging global opportunistic pathogen. Clin.Microbial.Rev. 2012; 25(1):2-41.
8. Clinical and Laboratory standards institute (CLSI), performance standards for antimicrobial susceptibility testing, 18th informational supplements CLSI Document M 100 January-2012.
9. Yu Lin Wang, Marco R. Scipione, Yanina Dubrovskaya, John Papadopoulos, Monotherapy with Fluoroquinolone or Trimethoprim-Sulfamethoxazole for treatment of S. maltophilia infections. Antimicrobial Agents and Chemotherapy. 2014; 58(1):176-182.
10. Mustafa Gokhan Gozel, Cem Celik, Nazif Elaldi S. maltophilia infection in Adults: Primary Bacteremia and Pneumonia. Microbiol. 2015; 8(8):1-7.
11. Emase Juhasz, Gergely Krizsan, Gyorgy Lengyel, GaborGrosz, Julia Pongracz and Katalin Kristof, Infection and colonization by S. maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary. Annals of Clinical Microbiology and Antimicrobials.2014; 333(13):1-7.
12. Wei Jia, Jiayuan Wang, Haotong Xu and Gang Li, Resistance of S. maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms. Int. J.Environ.Res.Public Health.2015; 15(2):5177-5195.
13. Ji Hyeon Baek, Chang Oh Kim, Su Jin Jeong, Nam Soo Ku et. al., Clinical factors Associated with acquisition of Resistance to Levofloxacin in S. maltophilia. Yonsei Med.J. 2014; 55(4):987-993.
14. Farrell DJ, Sader HS, Jones RN, Antimicrobial susceptibilities of a worldwide collection of S. maltophilia isolates tested against tegecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 2010; 54(6):2735-2737.
15. Hae-Sun Chung, Seong Geun Hong, Young Ree Kim, Kyeong Seob Shin et.al., Antimicrobial susceptibility of S. maltophilia Isolates from Korea, and the Activity of Antimicrobial Combinations against the Isolates. Infectious Diseases, Microbiology et Parasitology.2013; 28(1):62-66.
